Inhibition of PCSK9 with evolocumab modulates lipoproteins and monocyte activation in high-risk ASCVD subjects

ABSTRACT: Inhibition of PCSK9 with evolocumab modulates lipoproteins and monocyte activation in high-risk ASCVD subjects

PROVIDER: PRJNA1071588 | ENA |

REPOSITORIES: ENA